未登録の方はこちらから登録できます。
TEL．03-5812-5270
FAX．03-3831-0495
E-mail：info@spi-information.com
市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。
当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。
China Pharma Outsourcing Annual Review 2009
2009年度版 中国の医薬アウトソーシングの年次評価
2009年は、世界中のすべての業界にとって、苦しい年であると認識されており、金融危機は、世界レベルで製薬およびバイテク業界を激変させました。世界および中国の医薬アウトソーシング業界も、大きな影響を受け、中国の医薬アウトソーシング業界は、過去の成長経路に比べると、大幅な後退に苦しみました。
しかし、中国の医薬アウトソーシング業界のほぼすべてのサービス分野において、アウトソーシングの需要が大幅に減少しましたが、2009年における成長率は、依然として非常に著しいものがあります。さらに、医薬アウトソーシングにおいて依然として中国が持つ数々の利点に加え、多数の新たな要素が、さらに成長させる見込みです。
本レポートは、まず、世界の医薬およびバイテク業界が、危機によりどのような影響を受けているのかについて詳細に分析し、そして、過去12ヶ月間において、中国の医薬アウトソーシング業界が困難をいかに切り抜けてきたかを分析しました。
また、世界中の企業（大手製薬およびR&Dを重点的に取り組むバイテク企業）による中国におけるアウトソーシング活動など、2009年に起きたすべての主な出来事について、要約しました。
さらに、詳細な分析と調査に基づいた展望、つまり、一般的な世界の医薬アウトソーシングおよび中国の医薬アウトソーシングが2010年にはどのように変化しているか、予測しました。
本レポートの最も注目すべき特徴は、中国の医薬アウトソーシング業界におけるアウトソーシングサービス提供企業の現在のトップ10社の詳細な概要が含まれていることであり、中国の医薬アウトソーシング業界のトップ10社が特定されたのは、初めてのことです。
本レポートは、過去に中国の医薬アウトソーシング業界で何が起きたのかをはっきり、かつ深く理解することができるだけでなく、それが今後どう変化していくかをよりよく理解することができます。また、本レポートは、製薬、バイテク、アウトソーシングサービス、および中国の医薬アウトソーシングに関心を持つ財政投資などにおけるすべての組織や専門家にとって、必読書であります。
目次
- Scope of the Report
- About the Author
- Executive Summary
-
Review of Market Development in 2009
- Review on what happened to the global pharma and biotech industries in 2009
- Review on what happened to the Chinese pharma outsourcing industry in 2009
- Review on market development of Chinese pharma outsourcing industry in 2009
- Review on 2009 growth drivers of the Chinese pharma outsourcing industry
- Review on major activities in 2009
- Chinese service providers strengthening their service capability
- Review on major events in 2009
Outlook of 2010- How global pharma and biotech industries will move in 2010
- Strategies major pharma companies will take in 2010
- How global pharma outsourcing will be affected in 2010
- New strategies major pharma will likely implement in selecting their service providers
- Outlook of Chinese pharma outsourcing industry in 2010
- How each service sector of Chinese pharma outsourcing industry will move in 2010
- New development trends in the Chinese pharma outsourcing industry in 2010
- Chapter 1. Review of Market Development in 2009
-
Summary
1.1 Introduction
1.2 What happened to the global pharmaceutical and biotech industries in 2009?Analysis of the impacts of the financial crisis on both pharma and biotech industries1.3 What happened to the global pharma outsourcing industry in 2009?Analysis of the impacts of the financial crisis on the global pharma outsourcing industry1.4 How did Chinese pharma outsourcing industry weather the crisis?Analysis of the impacts of the financial crisis on the Chinese pharma outsourcing industry1.5 How was each service sector affected by the financial crisis?
1.4.1 What did JZMed predict at the beginning of 2009?
1.4.2 How did the Chinese pharma outsourcing industry actually move in 2009?Analysis of the impacts of the financial crisis on each service sector of the Chinese pharma outsourcing industry and their current market sizes
1.5.1 Early stage drug discovery servicea. Analysis of the impacts of the financial crisis on early stage drug discovery service
b. Current market size of early stage drug discovery service1.5.2 Preclinical research servicea. Analysis of the impacts of the financial crisis on preclinical research service
b. Current market size of preclinical research service1.5.3 Clinical research servicea. Analysis of the impacts of the financial crisis on clinical research service
b. Current market size of clinical research service1.5.4 Contract manufacturing servicea. Analysis of the impacts of the financial crisis and other factors on contract manufacturing service1.6 An overview of the current state of the Chinese pharma outsourcing industry
b. Current market size of contract manufacturing service1.6.1 Three development stages in the short history of the Chinese pharma outsourcing industry
1.6.2 Current overall state of the Chinese pharma outsourcing industry
1.6.3 Current total market size of the Chinese pharma outsourcing industry
1.6.4 Current service capability of the Chinese pharma outsourcing industrya. Current service capability in early stage drug discovery
b. Current service capability in preclinical research
c. Current service capability in late stage development
d. Current service capability in contract manufacturing1.6.5 Geographic distributions of Chinese service providers - Chapter 2. Review of Major Events and Industry Developments in 2009
-
Summary
2.1 Introduction
2.2 Major pharma companies continue spending and expanding their operations in Chinaa. Bayer Schering will invest $129 M to establish an R&D center in China2.3 Foreign biotech companies set up their R&D divisions in China
b. Novartis expects its China sales revenue to grow by 45% in 2009 and invests $1.25 B to build its third global R&D center in China
c. Eli Lilly announced to double its employee size and expand its operation in China
d. GSK targets China's vaccine market
e. Merck AG to train Chinese pharmacists
f. Novozymes plans to manufacture hyaluronic acid (bHA) in China
g. Sanofi-Aventis is going to relocate and further expand its China manufacturing facilities in Hangzhou
h. Pfizer announced research collaborations with two Chinese institutions
i. Boehringer Ingelheim to further expand its China operationa. FORMA Therapeutics established an R&D center in Beijing2.4 What happened to the CMO sector of the Chinese pharma outsourcing industry in 2009?
b. AlphaRx opened an R&D center in ChinaAnalysis of the development of contract manufacturing service in China in 20092.5 State Council issued special guidelines to encourage local government to improve environment for outsourcing service
2.6 Increasing numbers of multinational pharma outsourcing service providers have entered the Chinese market2.6.1 Foreign CROs opened subsidiaries/divisions in Chinaa. e-Therapeutics set up a new site in Nanjing to offer computational services
b. SGS opened new micro test lab in China
c. Sparta brought pharma quality management service to Asia
d. XBL opened its China lab
e. LGC opened its China office to raise local lab standards2.6.2 Foreign CROs formed JVs or partnerships with Chinese counterpartsa. Cogenics partnered with SinoGenoMax to offer genomic services in China
b. GVK formed partnership with Excel PharmaStudies
c. Clinilabs formed partnership with H&J2.6.3 Foreign CROs acquired Chinese counterparts to enter the Chinese marketa. ReSearch bought Chinese CRO Paramax International2.7 China-based CROs formed partnerships/alliances to strengthen their service capability
b. CBI acquired Shanghai-based GL Biochem to enter the booming peptide outsourcing market in China
c. PerkinElmer acquired Chinese diagnostic company to enter the Chinese market
d. PPD to acquire Exel PharmaStudies to strengthen its position in Chinaa. Two Shanghai-based Chinese CROs formed alliance2.8 Major outsourcing deals struck in 2009 between foreign pharma/biotech companies and China-based service providers
b. ChemWerth formed partnership with Tianjin Tianyao Pharmaceuticals Co.
c. Twenty CROs in Guangzhou formed an alliancea. BioDuro struck contracts with AstraZeneca and Roche on drug discovery research2.9 Chinese CROs expanded service capability
b. HD Biosciences secured contract with CellCentric for compound screening and other drug discovery work
c. ChemPartner successfully secured a series of contractsa. Asymchem Laboratories opened a high potency API manufacturing facility in Tianjin2.10 Venture capitals invested in Chinese CROs
b. Sundia MediTech acquired protein folding technologya. A $15 M investment made by Kleiner Perkins into Chinese CRO Jinsite - Chapter 3. Current Top Ten Players
-
Summary
3.1 Introduction
3.2 Evaluation of China-based pharma outsourcing service providers
3.3 Classification of players
3.4 Classification and definition of service capability
3.5 Selection of top ten players of Chinese pharma outsourcing industry
3.6 Description of top ten players - Chapter 4. Outlook of 2010
-
Summary
4.1 Introduction
4.2 Global pharma and biotech industries have been significantly altered by the financial crisis4.2.1 A totally different biotech industry after the financial crisis4.3 How will the global pharma outsourcing be affected?
4.2.2 Major pharma companies have become stronger than ever4.3.1 Challenges facing global pharma and biotech companies
4.3.2 New operation strategies pharma/biotech industry will likely implement in 2010 and near future
4.3.3 How will the global pharma outsourcing industry be likely affected?1. Outsourcing demands by major pharma companies will likely still remain strong in following areas
2. Outsourcing demands by major pharma will likely become weak in the following areas
3. New strategies major pharma will likely implement in selecting their service providers
4. Outsourcing demands by small biotech companies will likely remain strong in the following areas
5. Outsourcing demands by small biotech companies will become weak in the following areas
6. Summary of the changes in outsourcing demands in 2010 by both pharma and biotech industries4.3.4 What types of CROs/CMOs will become preferred service providers?4.4 How will pharma outsourcing develop in China in 2010?
4.5 How will each service sector of Chinese pharma outsourcing industry move in 2010?4.5.1 Early stage drug discovery4.6 New development trends in the Chinese pharma outsourcing industry in 2010
4.5.2 Preclinical development
4.5.3 Clinical research
4.5.4 Contract manufacturing
4.5.5 Summary of the growth forecasts of the Chinese pharma outsourcing industry in 20104.6.1 More consolidations4.7 Key issues still facing all China-based pharma outsourcing service providers in 2010
4.6.2 Chinese pharma outsourcing industry will gradually become mature with more, one-stop service providers to emerge
4.6.3 Licensing of generic drugs by major pharma companies4.7.1 Fast rising of labor cost
4.7.2 Abiding by the international rule of the game
4.7.3 Competition from neighboring developing countries
4.7.4 Competition from Indian pharma outsourcing companies1. Strengths and weakness of each country in pharma outsourcing4.8 How to effectively conduct outsourcing in China
2. Current market sizes of each country4.8.1 Advices to companies sourcing APIs and raw materials in China4.9 Key benefits of outsourcing to China
4.8.2 Advices to small biotech companies outsourcing in China - About JZMed, Inc.
- List of Tables
-
Table 1. Number of companies having announced restructure during the financial crisis
Table 2. Ortho-McNeil Jassen Pharmaceuticals outsourced early stage drug R&D projects to both Chinese and Indian companies simultaneously
Table 3. More examples of outsourcing collaborations happened recently between major Western pharma companies and Chinese companies/research organizations
Table 4. Market development of each service sector of Chinese pharma outsourcing industry in 2009
Table 5. Comparison of market values in 2009 between China's CRO sector and its CMO sector
Table 6. Summary of major events and activities happened to the Chinese pharma outsourcing industry in 2009
Table 7. Classification and definition of service capability of contract research organization
Table 8. Current top ten pharma outsourcing service providers in China
Table 9. Brief summary of WuXi PharmaTech
Table 10. Development history of WuXi PharmaTech (revenue and staff size)
Table 11. Company profile of WuXi PharmaTech
Table 12. Brief summary of ChemPartner
Table 13. Company profile of ChemPartner
Table 14. Brief summary of Asymchem Lab
Table 15. Company profile of Asymchem Lab
Table 16. Brief summary of BioDuro
Table 17. Company profile of BioDuro
Table 18. Brief summary of Venturepharm Lab
Table 19. Company profile of Venturepharm Lab
Table 20. Brief summary of Pharmaron
Table 21. Company profile of Pharmaron
Table 22. Brief summary of Medicilon
Table 23. Company profile of Medicilon
Table 24. Brief summary of Sundia Meditech
Table 25. Company profile of Sundia Meditech
Table 26. Brief summary of ShanghaiBio
Table 27. Company profile of ShanghaiBio
Table 28. Brief summary of Excel PharmaStudies
Table 29. Company profile of Excel PharmaStudies
Table 30. Summary of forecasted development trends of global pharma outsourcing industry in 2010 and beyond
Table 31. 2010 Market development forecast of Chinese pharma outsourcing industry
Table 32. 2010 Market development forecast of each service sector of the Chinese pharma outsourcing industry
Table 33. Growth forecast of China's CRO and CMO market in 2010 - List of Figures
-
Figure 1. Graphic display of the number of companies having announced restructure during the financial crisis
Figure 2. Predicted impacts of the financial crisis on Chinese pharma outsourcing industry
Figure 3. Quarter-over-quarter earning development trend of Chinese pharma outsourcing market during the financial crisis
Figure 4. Market value of each service sector in 2009
Figure 5. An overview of the current situation of the Chinese pharma outsourcing industry
Figure 6. Chinese pharma outsourcing market: Development history and current size
Figure 7. Comparison of China's CRO and CMO market values in 2009
Figure 8. Number of service providers in each service sector of the Chinese pharma outsourcing industry
Figure 9. Classification and rating of China-based CROs and CMOs
Figure 10. Estimated 2009 service revenues of top ten China-based pharma outsourcing service providers
Figure 11. WuXi PharmaTech's staff growth history and forecast
Figure 12. WuXi PharmaTech's revenue growth history and forecast
Figure 13. Strategies likely to be implemented by both major pharma and small biotech companies in 2010 and the near future
Figure 14. Forecasted market value of each service sector of the Chinese pharma outsourcing industry in 2010
Figure 15. Forecasted China's CRO and CMO market values in 2010
発刊日
2009/11/01
体裁
PDF / 162ページ
販売価格
1,385USD
発行
JZMed Inc
備考
※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。
関連カテゴリ
購入・お問い合わせ
